Merck enters into a clinical trial collaboration and supply agreement with Adcendo

[출처/시간] Briefing.com - 7:08 AM ET, 05/26/2026

Adcendo ApS announce that it has entered into a clinical trial collaboration and supply agreement with MSD. ADCE-T02, a potential best-in-class topoisomerase-1 (Topo-1) inhibitor-based ADC targeting Tissue Factor, will be evaluated in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in a new Phase Ib study in patients with advanced solid tumors.Under the terms of the Agreement, MSD will provide pembrolizumab to Adcendo, which will be the sponsor of the Phase Ib clinical combination trial. Adcendo and MSD each retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies.Adcendo anticipates dosing the first patient in the Phase Ib combination study in 2H 2026 and will investigate the safety, tolerability and preliminary efficacy of escalating doses of ADCE-T02 in combination with standard dose pembrolizumab in patients with advanced solid tumors.